Mostrar el registro sencillo del ítem

dc.contributor.authorRamos-Rodríguez, Juan José
dc.contributor.authorJiménez Palomares, Margarita 
dc.contributor.authorMurillo-Carretero, María Isabel
dc.contributor.authorInfante-Garcia, Carmen
dc.contributor.authorBerrocoso Domínguez, Esther María 
dc.contributor.authorHernandez-Pacho, Fernando
dc.contributor.authorLechuga Sancho, Alfonso María 
dc.contributor.authorCozar-Castellano, Irene
dc.contributor.authorGarcía Alloza, Mónica 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2025-01-26T11:47:03Z
dc.date.available2025-01-26T11:47:03Z
dc.date.issued2015-07-26
dc.identifier.issn1873-3360
dc.identifier.issn0306-4530
dc.identifier.urihttp://hdl.handle.net/10498/34813
dc.description.abstractAging remains the main risk factor to suffer Alzheimer's disease (AD), though epidemiological studies also support that type 2 diabetes (T2D) is a major contributor. In order to explore the close relationship between both pathologies we have developed an animal model presenting both AD and T2D, by crossing APP/PS1 mice (AD model) with db/db mice (T2D model). We traced metabolic and cognitive evolution before T2D or AD pathology is present (4 weeks of age), when T2D has debuted but no senile plaques are present (14 weeks of age) and when both pathologies are well established (26 weeks of age). APP/PS1xdb/db mice showed an age-dependent synergistic effect between T2D and AD. Significant brain atrophy and tau pathology were detected in the cortex by 14 weeks, that spread to the hippocampus by 26 weeks of age. Severe cognitive impairment was also detected as soon as at 14 weeks of age. Interestingly, in APP/PS1xdb/db mice we observed a shift in Aβ soluble/insoluble levels, and whereas more toxic soluble species were favoured, senile plaques (SP) were reduced. An overall increase of microglia activation was observed in APP/PS1xdb/db mice. We also found exacerbated hemorrhagic burden in APP/PS1xdbd/db mice, suggesting that blood brain barrier alterations may be responsible for the early pathological features observed. Moreover, metabolic parameters can predict many of these alterations, supporting a role for T2D in AD pathology. This new model provides a relevant tool to further explore the relationship between T2D, AD and vascular implications, offering the possibility to assess therapeutic approaches, that by improving T2D metabolic control could delay or prevent AD pathology.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.sourcePsychoneuroendocrinology, Vol. 62, 2015, pp. 69-79es_ES
dc.subjectAlzheimer's diseasees_ES
dc.subjectamyloides_ES
dc.subjecthemorrhagees_ES
dc.subjectphospho-taues_ES
dc.subjecttype 2 diabeteses_ES
dc.subjectvascular dementiaes_ES
dc.titleCentral vascular disease and exacerbated pathology in a mixed model of type 2 diabetes and Alzheimer's diseasees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsclosed accesses_ES
dc.identifier.doi10.1016/j.psyneuen.2015.07.606
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem